source
- Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemiaMarrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
- Biotech boards see more women, but CEO roles remain largely male-dominatedWomen now occupy roughly 29% of biotech board seats, a notable rise from about one‑fifth a few years ago, according to the latest Bedford Group Transearch report. Despite that progress, female CEO…